Economic Analysis - January 1, 2013
AstraZeneca buys US Ardea Biotech
AstraZeneca has acquired the San Diego-based biotech firm Ardea Biosciences for 1.26 billion USD, approximately 8.4 billion SEK. The deal was presented in April, just months after AstraZeneca announced substantial restructuring in research and development at its operations in Södertälje, resulting in the lay-off of about 1200 researchers and personnel. “There is a lot of […]
Economic Analysis - January 1, 2013
Sobi – no bargain at this level
The Swedish biotech company Swedish Orphan Biovitrum (Sobi) works within specialty pharma. The company was formed in 2001 as Biovitrum, a spinoff from Pharmacia, and registered on the stock market in 2006. In 2009 Biovitrum acquired the company Swedish Orphan for 3.9 billion Swedish crowns, a price many analysts considered too high. The new company […]
Economic Analysis - December 13, 2012
Impressive Deal by action pharma
The Danish biotech firm Action Pharma impressed the market in early May by selling a drug candidate to pharmaceutical company Abbott for 110 million USD, approximately 780 million Swedish crowns. The drug candidate goes under the name of AP214 and is used to prevent acute kidney injury during cardiac surgery. The whole amount, 110 million […]
